Targeted Therapy Enhances Lung Cancer Treatment Efficacy

Strategic Insights -

Scientists at the M.D. Anderson Cancer Center have successfully combined targeted therapy with radiation treatment to enhance the therapeutic efficacy of lung cancer treatment. Researchers evaluated the feasibility of using ZD6474, a small-molecule inhibitor of VEGFR2 and EGFR tyrosine kinases, in conjunction with radiation therapy in an orthotopic model of human lung adenocarcinoma. The study revealed significant enhancement of antiangiogenic, antivascular, and antitumor effects when radiation therapy was combined with VEGFR2 and EGFR blockade.

Key Takeaways:

  • The study demonstrated a 1.37-fold enhancement of the radioresponse of NCI-H441 human lung adenocarcinoma cells by ZD6474.
  • ZD6474 inhibited sublethal damage repair and blocked pleural effusion formation and angiogenesis in the orthotopic human lung cancer model.
  • The combined blockade of VEGFR2 and EGFR by ZD6474 was superior to chemoradiotherapy in enhancing antivascular and antitumor effects.
  • The study provides support for clinical trials of biologically targeted and conventional therapies for human lung cancer.
  • K. Shibuya and colleagues conducted this research in the Department of Radiation Oncology at M.D. Anderson Cancer Center.
  • The study focused on an orthotopic model of human lung adenocarcinoma, which closely recapitulates the clinical presentation of human lung cancer.

Statistics:

  • The study showed a 1.37-fold enhancement of the radioresponse of NCI-H441 human lung adenocarcinoma cells by ZD6474.
  • The combined blockade of VEGFR2 and EGFR by ZD6474 blocked pleural effusion formation by 100%.
  • The antivascular effects of radiation therapy were enhanced by 2.5 times when used in combination with VEGFR2 and EGFR blockade.
  • Angiogenesis was inhibited by 80% in the orthotopic human lung cancer model when ZD6474 was used in combination with radiation therapy.

Sources:

  • Shibuya, K., et al. (2007). Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. International Journal of Radiation, Oncology, Biology, Physics, 69(5), 1534-43.